Followers | 82 |
Posts | 5373 |
Boards Moderated | 0 |
Alias Born | 11/29/2016 |
Wednesday, April 17, 2024 8:38:27 AM
Recent IOVA News
- Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/01/2024 10:01:00 AM
- Iovance Biotherapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 04/30/2024 10:01:00 AM
- Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/19/2024 09:15:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/22/2024 09:30:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:56:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:53:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:52:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:52:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:51:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:50:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 01:00:20 PM
- Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 03/04/2024 11:30:00 AM
- Iovance Biotherapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 03/01/2024 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:30:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:05:21 PM
- Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates • GlobeNewswire Inc. • 02/28/2024 09:01:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:53:39 PM
- Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024 • GlobeNewswire Inc. • 02/22/2024 01:45:21 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/21/2024 09:44:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 10:23:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:21:48 PM
- Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock • GlobeNewswire Inc. • 02/20/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:03:55 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM